Navamedic ASA (OSL:NAVA)

Market Cap	318.95M -41.9%
Revenue (ttm)	574.31M +9.7%
Net Income	-23.16M
EPS	-1.04
Shares Out	23.98M
PE Ratio	n/a
Forward PE	70.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,236
Open	13.00
Previous Close	12.70
Day's Range	12.95 - 13.30
52-Week Range	12.50 - 26.50
Beta	0.24
Analysts	Strong Buy
Price Target	21.40 (+60.9%)
Earnings Date	Oct 29, 2026

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 38
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2025, Navamedic ASA's revenue was 565.36 million, an increase of 6.38% compared to the previous year's 531.44 million. Losses were -23.54 million, 329.1% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for NAVA stock is "Strong Buy." The 12-month stock price target is kr 21.40, which is an increase of 60.90% from the latest price.

Price Target

kr 21.40

(60.90% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 23, 2026

Data Sources Report a data error